VXRT Stock Overview
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.69|
|52 Week High||US$24.90|
|52 Week Low||US$4.86|
|1 Month Change||-7.21%|
|3 Month Change||-23.19%|
|1 Year Change||-13.34%|
|3 Year Change||145.06%|
|5 Year Change||n/a|
|Change since IPO||-21.29%|
Recent News & Updates
Vaxart: Differentiated Covid Oral Route Remains Viable
In an environment where injection-type vaccines are proving to offer somewhat reduced protection against the delta variant, the risks of being infected and transmitting the virus to others remain high. In this case, Vaxart's oral tablet vaccine, not to be confused with the antiviral pills being produced by Merck and Pfizer, does make a lot of sense for preventive purposes. This differentiation seems to have been ignored by the market, with Vaxart's shares trending lower. Considering potential sales of $1 billion, a target share price of $15 remains a moderate one, but it is better to remain prudent with the road leading to Phase 3 trials likely to be a long one. The implications of Vaxart's development could have a significant effect on Covid-19 progress, namely by encouraging a lot of people like myself to be orally inoculated instead of being jabbed again and again.
Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program
On Oct 26, Vaxart announced dosing of the first subject in their Phase 2 COVID-19 oral tablet vaccine trial. The company has also updated their corporate presentation recently. I take a close look at Vaxart's COVID-19 program and share my thoughts.
Vaxart: An Update
On Oct. 1, Merck announced their oral COVID pill reduces hospitalization or death by 50% and the company will seek EUA as soon as possible. Merck's good news seemed to cause a double-digit % stock price drop in COVID vaccine developers, including VXRT. VXRT's COVID program is still on, but with an incredibly slow speed and an apparent lack of focus.
|VXRT||US Biotechs||US Market|
Return vs Industry: VXRT underperformed the US Biotechs industry which returned 1.8% over the past year.
Return vs Market: VXRT underperformed the US Market which returned 19.4% over the past year.
|VXRT Average Weekly Movement||7.7%|
|Biotechs Industry Average Movement||8.8%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: VXRT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: VXRT's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.
Vaxart Fundamentals Summary
|VXRT fundamental statistics|
Is VXRT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VXRT income statement (TTM)|
|Cost of Revenue||US$41.81m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.51|
|Net Profit Margin||-5,414.57%|
How did VXRT perform over the long term?See historical performance and comparison
Is Vaxart undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: VXRT ($6.69) is trading above our estimate of fair value ($1.16)
Significantly Below Fair Value: VXRT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VXRT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: VXRT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VXRT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VXRT is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (2.8x).
How is Vaxart forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VXRT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: VXRT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VXRT's is expected to become profitable in the next 3 years.
Revenue vs Market: VXRT's revenue (84.3% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: VXRT's revenue (84.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VXRT's Return on Equity is forecast to be high in 3 years time
How has Vaxart performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VXRT is currently unprofitable.
Growing Profit Margin: VXRT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VXRT is unprofitable, and losses have increased over the past 5 years at a rate of 35.2% per year.
Accelerating Growth: Unable to compare VXRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VXRT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: VXRT has a negative Return on Equity (-31.02%), as it is currently unprofitable.
How is Vaxart's financial position?
Financial Position Analysis
Short Term Liabilities: VXRT's short term assets ($192.3M) exceed its short term liabilities ($12.6M).
Long Term Liabilities: VXRT's short term assets ($192.3M) exceed its long term liabilities ($23.6M).
Debt to Equity History and Analysis
Debt Level: VXRT is debt free.
Reducing Debt: VXRT currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VXRT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VXRT has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 30.8% each year.
What is Vaxart current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VXRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VXRT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VXRT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VXRT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VXRT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andy Floroiu (48 yo)
Mr. Cezar Andrei Floroiu, also known as Andy, M.B.A., also serves as the Chief Executive Officer and Principal Financial Officer at Vaxart, Inc. since June 14, 2020 and serves as its Director since April 2...
CEO Compensation Analysis
Compensation vs Market: Andy's total compensation ($USD2.55M) is about average for companies of similar size in the US market ($USD2.36M).
Compensation vs Earnings: Insufficient data to compare Andy's compensation with company performance.
Experienced Management: VXRT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: VXRT's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
Vaxart, Inc.'s employee growth, exchange listings and data sources
- Name: Vaxart, Inc.
- Ticker: VXRT
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$882.865m
- Shares outstanding: 125.50m
- Website: https://vaxart.com
Number of Employees
- Vaxart, Inc.
- 170 Harbor Way
- Suite 300
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/02 23:42|
|End of Day Share Price||2021/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.